From the publishers of JADPRO
Updates for the Advanced Practitioner
Myeloproliferative Neoplasms
Subscribe
About
Contact
MENU
Home
Visit JADPRO Online
In The News
In The Literature
Videos
Fast Facts
More Updates
Advertisement
In The News
Oncology Nurse Advisor
Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
American Journal of Managed Care
New Guideline Released on Managing Complications in Polycythemia Vera
Oncology Nurse Advisor
Case Study: Myelofibrosis Diagnosis and Early Intervention
Cure
Encouraging Preliminary Results in Myelofibrosis Trial Lead to Enhancements in Phase 2
HemOnc Today
Ruxolitinib-Azacitidine Combination Shows ‘Synergistic Efficacy’ for Myelofibrosis
Oncology Nurse Advisor
Smoking Ups Risk of Myeloproliferative Neoplasms Overall and by Subtype
Targeted Oncology
Ruxolitinib May Prove Beneficial in Combination for Myelofibrosis
Cure
Through Thick and Thin: Monitoring Blood Clots With ET
American Journal of Managed Care
A Minority of Patients With High-Risk Polycythemia Vera Receive Cytoreductive Medication
Oncology Learning Network
Adding Hydroxycarbamide to Aspirin of Little Benefit to Certain Older Patients with Essential Thrombocythemia
Cure
Relatives of Patients With Myeloid Blood Cancer at Two-Fold Risk of Disease
Targeted Oncology
The Role of JAK2 Inhibition in Polycythemia Vera
Cure
New Tool Helps Patients With Myelofibrosis Time Stem Cell Transplantation for Better Outcomes
HemOncToday
Treatment of Myelofibrosis with JAK Inhibitors May Increase Risk for Aggressive Lymphoma
Science Daily
Structure of Protein Pair Provides Blueprint for Future Drugs
Cure
MPN Field ‘Hitting Its Stride,’ But More Work Is Needed
HemOnc Today
Prognostication in Myelofibrosis: Integrating Genetics into Routine Practice
Rare Disease Report
Five Facts About: Myeloproliferative Neoplasms (Infographic)
The ASCO Post
Study Findings on Novel Agents in Neoplastic Hematology
Cancer Network
Pacritinib May Benefit Patients with Myelofibrosis and Thrombocytopenia
HemOncToday
Ruxolitinib Therapy Appears Safe Prior to Allogeneic HSCT for Myelofibrosis
HemOncToday
Idasanutlin Active in Refractory Polycythemia Vera
Oncology Newswatch
Hypomethylators Are Safe and Effective in MPNs
HemOncToday
FDA Expands Clearance of Ipsogen JAK2 Assay for Myeloproliferative Neoplasms
Targeted Oncology
Sotatercept Boosts Hemoglobin in MPN-Associated Myelofibrosis
Cancer Network
Immunotherapies Could Play Role in CALR-Positive Myeloproliferative Neoplasms (Video)
OncLive
Expert Highlights RESPONSE Results With Ruxolitinib in Polycythemia vera
Targeted Oncology
Ropeginterferon Alfa-2b Has Long-Term Benefits in Polycythemia Vera
MPNforum Magazine
Fedratinib Rises
Hematol News
FDA Approves Test for Hematologic Cancer Detection
Medscape
Risk of Age-Related Macular Degeneration Higher With Myeloproliferative Neoplasms
Medscape
European LeukemiaNet Study on the Reproducibility of Bone Marrow Features in Masked Polycythemia Vera
ASCO Post
Myeloproliferative Neoplasms and Myelofibrosis: New Treatment Guidelines
Cancer Network
Fedratinib Reduced Spleen Volume in Ruxolitinib-Resistant Myelofibrosis
Oncol Nurse Adv
Unexplained Leukocytosis, Thrombocytosis in MPNs Warrants Evaluation for CML
PR Newswire
AOP Orphan and PharmaEssentia Announce Latest Clinical Results for Ropeginterferon alfa-2b in Polycythemia Vera
HemOnc Today
Lack of Transfusion Capabilities Linked to Underuse of Hospice for Blood Cancers
Nature.com
The Role of LNK/SH2B3 Genetic Alterations in Myeloproliferative Neoplasms and Other Hematological Disorders
Oncology Nursing News
Patients Often Not as Confident in Their Oral Medication Regimens as They Seem
Cure
Clinical Trials Are Crucial to Advance MPN Treatment
The ASCO Post
Reduced-Intensity vs Standard Conditioning Followed by ASCT in Myelodysplastic Syndrome
National Cancer Institute
Myelodysplastic/Myeloproliferative Neoplasms Treatment (PDQ®)
Oncology Nurse Advisor
Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
Modern Pathology
3q26.2/EVI1 Rearrangement is Associated With Poor Prognosis in Classical Philadelphia Chromosome-Negative Myeloproliferative Neoplasms
Medscape Oncology
Pacritinib Well Tolerated and Helpful in Myelofibrosis
ONS Voice
FDA Approves Marketing Ipsogen JAK2 RGQ PCR Kit to Help Evaluate Suspected Polycythemia Vera
Leukemia Foundation MPN News (PDF download)
Genetic Profiling: The Basis of a Groundbreaking Myelofibrosis Study
MPN Advocacy & Education
The Ultimate Blood Brothers
Medscape
Do We Know What Matters Most to Cancer Patients?
Oncology Nurse Advisor
Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
Mayo Clinic
Online Survey To Measure Nutritional Needs in Patients With Myeloproliferative Neoplasms
MedicalXpress
Genetic Profiling Can Guide Stem Cell Transplantation for Patients With Myelodysplastic Syndromes
OncLive
High Rates of Symptoms, Impairment, With Myeloproliferative Neoplasms
OncLive
Landscape for Myeloproliferative Disorders Becoming More Defined With Improved Treatments, Biomarkers
Oncology Nurse Advisor
Anxiety, Distress Common Among Patients With BCR-ABL-Negative MPNs
New Mexico Cancer Center News
Duration of Blood Storage Does Not Affect Outcomes for Patients Requiring Blood Transfusions
Northwestern Now
Rewired Cells Show Promise for Targeted Cancer Therapy
Cancer Connect
Interferon No Better Than Hydroxyurea and Associated With Worse Side Effects in Polycythemia Vera and Essential Thrombocythemia
Cancer Connect
5-Year Survival Improved With Early Use of Ruxolitinib in Myelofibrosis
MPN Advocacy & Education
Women with Myeloproliferative Neoplasms Appear to Have Successful Pregnancies
Cancer Connect
About PCROWD, Dana-Farber’s Tissue-Banking Study for Patients with Myeloproliferative Neoplasms, Smoldering Multiple Myeloma, Smoldering Waldenstrom’s Macroglobulemia, and Early Myelodysplastic Syndromes
Cure
Personalizing Treatment From Start to Finish in Polycythemia Vera
Cancer Connect
Jakafi Safe and Effective in Polycythemia Vera
Medical Life Sciences
New NCCN Guidelines Outline Diagnosis, Treatment Strategies for Myeloproliferative Neoplasms
Medscape Oncology
Ipilimumab Shows Impressive Activity After HSCT Failure
Cure
Study Examines Sexuality Symptoms in Patients With Myeloproliferative Neoplasms
CancerConnect.com
All Symptomatic Polycythemia Vera Patients may Benefit From Treatment With a JAK2 Inhibitor
The MPN Research Foundation
Anti-Fibrotic Drug Recruiting Patients Across the Country for Phase 2 Clinical Trial
Videos
Perspectives on the Collaborative Management of Myeloproliferative Neoplasms
Advertisement
Videos
Perspectives on the Collaborative Management of Myeloproliferative Neoplasms
Advertisement
Copyright © 2019 Harborside Press, LLC All rights reserved.
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our
Privacy Policy
to learn more.